Case Study: Stabilizing a Clinical-Stage Biotech’s PV Function During Organizational Transition
Client Profile
A small clinical-stage biotech with a hybrid operating model required a gap assessment and pharmacovigilance planning following the exit of internal staff.
Challenge
The client was at a critical transition point. Their Head of PV and remaining safety team members had recently exited. There was no one to oversee the case processing vendor,respond to study team questions, or support signal detection activities. At the same time, the company was entering a new agreement with a development partner and required a PV leader to initiate communication with the partner’s Safety team.
The client needed urgent support to:
- Re-establish internal PV oversight
- Negotiate a PV agreement with the new business partner
- Address undocumented processes and resolve SOP gaps
- Resolve compliance issues, including late reporting
- Laythe foundation for a PV system that could support future unpartnered assets
Perspective Pharmacovigilance’s Solution
Interim Leadership and Functional Rebuild
Perspective Pharmacovigilance installed an interim Head of PV to lead safety strategy and operations.
A PV QA and Quality Management specialist conducted a full gap assessment and led remediation efforts.
A Safety Operations team reestablished vendor oversight, restored sponsor case review, and reestablished control of the safety mailbox.
A Safety Scientist authored aggregate reports and implemented structured signal detection and safety governance processes.
Compliance Investigation and CAPA Development
PPV identified multiple compliance gaps, including late reporting and inadequate documentation.
The team collaborated closely with the client’s Quality function to develop CAPAs, formalize root cause analysis, and introduce process controls to prevent recurrence.
A CAPA tracking and escalation mechanism was implemented to maintain accountability.
Comprehensive Gap Assessment and Roadmap
PPV reviewed Safety Management Plans, DSURs, protocols, investigator brochures, SOPs, and associated documents.
The team conducted interviews across key functions and delivered an actionable roadmap prioritizing remediation activities.
Partner Engagement and Pharmacovigilance Agreement (PVA)
PPV initiated early communication with the new development partner and led negotiation of the PVA.
The agreement established clear expectations for safety responsibilities,workflow alignment, and inspection readiness.
PPV oversaw safety data migration and transition activities for ongoingpartnered studies.
Scalable PV System Design
PPV developed a scalable governance model capable of supporting both partnered programs and the client’s internal development portfolio. The system emphasized proactive oversight, documentation consistency, and readiness for future regulatory requirements.
Key Takeaways for Clinical-Stage Biotechs
This engagement highlighted several important lessons:
- Leadership gaps can introduce operational risk, making redundancy and visibility critical.
- Early governance and clear processes support resilience during organizational changes.
- Transparent, well-negotiated PV agreements strengthen partnerships and reduce inspection uncertainty.
- Scalable PV systems enable biotechs to grow without rebuilding core safety infrastructure.
Outcomes
1. PV Function Promptly Stabilized
Through rapid deployment of interim leadership and operational support, PPV restored full safety oversight during a critical transition period.
2. Compliance Risks Resolved
PPV identified late reporting and documentation issues and partnered with the client to implement structured CAPAs to prevent recurrence.
3. Partner Alignment Established
PPV led PVA negotiations and ensured alignment around safety data flow and inspection expectations from the outset of the partnership.
4. Cross-Functional Collaboration Strengthened
PPV worked effectively with PV, QA, Clinical, and Regulatory teams to establish clear governance and communication pathways.
5. Future-Ready PV System Delivered
The new PV framework supports both partnered and unpartnered programs and provides a scalable foundation for continued growth and regulatory readiness.
Conclusion
Organizational transitions can challenge even well-structured safety functions. With the right expertise and leadership, these challenges can be addressed quickly and effectively. Perspective Pharmacovigilance helps clients stabilize PV operations, resolve compliance risks, and build systems that grow with their development pipeline.
Contact us to learn how PPV can support your pharmacovigilance function during periods of growth or transition.
